Thomas G Wiggans

Thomas G Wiggans has an estimated net worth of $21.1 Million. This is based on reported shares across multiple companies, which include CymaBay Therapeutics, Inc., PEPLIN INC, TERCICA INC, SANGAMO BIOSCIENCES INC, PARDES BIOSCIENCES, INC., Forma Therapeutics Holdings, Inc., Dermira, Inc., Annexon, Inc., ONYX PHARMACEUTICALS INC, Somaxon Pharmaceuticals, Inc., Jasper Therapeutics, Inc., ABGENIX INC, and CONNETICS CORP.

2017 was Thomas G Wiggans's most active year for acquiring shares with 24 total transactions. Thomas G Wiggans's most active month to acquire stocks was the month of February. 2017 was Thomas G Wiggans's most active year for disposing of shares, totalling 39 transactions. Thomas G Wiggans's most active month to dispose stocks was the month of July. 2017 saw Thomas G Wiggans paying a total of $6,175,184.00 for 330,000 shares, this is the most they've acquired in one year. In 2020 Thomas G Wiggans cashed out on 1,939,539 shares for a total of $4,330,275.00, their largest year based on trade value.